CN1610549A - 用于治疗难治肿瘤的埃坡霉素衍生物 - Google Patents
用于治疗难治肿瘤的埃坡霉素衍生物 Download PDFInfo
- Publication number
- CN1610549A CN1610549A CNA028052447A CN02805244A CN1610549A CN 1610549 A CN1610549 A CN 1610549A CN A028052447 A CNA028052447 A CN A028052447A CN 02805244 A CN02805244 A CN 02805244A CN 1610549 A CN1610549 A CN 1610549A
- Authority
- CN
- China
- Prior art keywords
- methyl
- alkyl
- hydrogen
- dihydroxy
- thiazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 85
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 239000001257 hydrogen Substances 0.000 claims description 84
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 70
- -1 epothilone compounds Chemical class 0.000 claims description 66
- 150000002431 hydrogen Chemical group 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000002252 acyl group Chemical group 0.000 claims description 40
- 229930013356 epothilone Natural products 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 32
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 32
- 125000003107 substituted aryl group Chemical group 0.000 claims description 29
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 29
- 229920002554 vinyl polymer Polymers 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 150000002118 epoxides Chemical class 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- IJVLVRYLIMQVDD-UHFFFAOYSA-N 1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-N 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000005594 diketone group Chemical group 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract description 18
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract description 15
- 229940123237 Taxane Drugs 0.000 abstract description 12
- 229930012538 Paclitaxel Natural products 0.000 description 30
- 229960001592 paclitaxel Drugs 0.000 description 30
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 206010059866 Drug resistance Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 12
- 206010033128 Ovarian cancer Diseases 0.000 description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 description 10
- 231100000682 maximum tolerated dose Toxicity 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000036457 multidrug resistance Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003005 anticarcinogenic agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229960002014 ixabepilone Drugs 0.000 description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 229920003026 Acene Polymers 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OEDUIFSDODUDRK-UHFFFAOYSA-N 5-phenyl-1h-pyrazole Chemical compound N1N=CC=C1C1=CC=CC=C1 OEDUIFSDODUDRK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001044369 Amphion Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
- 101000835651 Echinococcus multilocularis Tubulin beta-2 chain Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MNFVBIKSDJJGAO-UHFFFAOYSA-N N1C=CC=C1.C1(=CC=CC=C1)C1=NOC=C1 Chemical class N1C=CC=C1.C1(=CC=CC=C1)C1=NOC=C1 MNFVBIKSDJJGAO-UHFFFAOYSA-N 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 150000001854 cinnolines Chemical class 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000025090 microtubule depolymerization Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940100661 nasal inhalant Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- ONCNIMLKGZSAJT-UHFFFAOYSA-N thieno[3,2-b]furan Chemical compound S1C=CC2=C1C=CO2 ONCNIMLKGZSAJT-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
本发明公开了一种治疗哺乳动物肿瘤的方法,特别是用紫杉烷(taxane)类抗肿瘤药物治疗证明产生抗药性的人类肿瘤的方法。该方法对于用紫杉烷治疗开始无效或在治疗的过程中对紫杉烷产生抗药性的肿瘤有效。该方法包括服用选自式I的埃坡霉素(Epothilone)衍生物:[化学式图]。本发明的埃坡霉素衍生物不但能提高对用紫杉烷肿瘤药物治疗产生抗药性的肿瘤的治疗效力,而且口服有效。
Description
交叉引用有关申请
本申请要求申请号为60/269,858,申请日为2001年2月20日的临时申请的优先权,其全文在此引用作为参考。
发明领域
本发明涉及某些有效的埃坡霉素(Epothilone)类似物在治疗用其它化疗剂已证明产生抗药性的肿瘤的应用。
发明背景
埃坡霉素是用于制药领域的大环内酯类化合物。例如埃坡霉素A和B,结构为:
埃坡霉素A 埃坡霉素B
R=H R=Me
可以发现发挥类似于紫杉醇(TAXOL)的微管-稳定效应,因此具有对抗迅速增生细胞的细胞毒性作用,如可用于肿瘤细胞或其它高度增生细胞疾病,参见Hofle等,Angew.Chem.Int.Ed.Engl.,35卷,No.13/14,1567-1569(1996)、WO93/10121公开于1993年5月27日;及WO97/19086,公开于1997年5月29日。
埃坡霉素A和B的衍生物和类似物已经人工合成并且可用于治疗各种癌症及其他不正常的增生性疾病。这些类似物公开在Hofle等,Id.;Nicolaou等,Angew.Chem.Int.Ed.Engl.,Vol.36,No.19,2097-2103(1997)和Su等,Angew.Chem.Int.Ed.Engl.,36卷,No.19,2093-2097(1997)。在有些情况下,埃坡霉素衍生物已表现出增强的性质,超过埃坡霉素A和B本身。本发明涉及发现两种这样的埃坡霉素衍生物,即它们可用于治疗已证明对其它化疗剂,如紫杉烷(taxane)族化合物的溶瘤细胞剂产生抗药性的某些癌症。
发明概要
根据本发明,可以用选自式I的埃坡霉素衍生物治疗对紫杉烷抗肿瘤剂治疗表明具有临床抗药性的肿瘤:
其中G、P、Q和R的意义如下。式I代表的化合物已表现出显著增强的效力,超过已知化疗剂,例如上述埃坡霉素A和B以及某些其它包括在紫杉烷系列的化合物。式I化合物的另一优势在于口服有效,这与大多数抗肿瘤药物不同。
附图简要说明
图1是柱状图,显示本发明的一种化合物的细胞毒性谱。
图2(A)是两种埃坡霉素衍生物对Pat-7人类卵巢癌细胞的抗肿瘤活性比较。
图2(B)是本发明一种化合物的剂量反应关系图。
图3是两种埃坡霉素衍生物对A2780Tax人类卵巢癌细胞的抗肿瘤活性比较。
图4是一种口服埃坡霉素衍生物以及静脉注射埃坡霉素衍生物对Pat-7人类卵巢癌细胞的抗肿瘤活性比较。
图5显示几个埃坡霉素类似物的结构。
发明详述
本发明对用化疗剂如紫杉烷类治疗产生抗药性的肿瘤提供了有益的治疗方法。这里所用的术语“对治疗的抗药性”既包括最初用一种化疗剂治疗无反应的肿瘤,又包括开始有反应而治疗过程中产生抗药性的肿瘤。本发明方法的有效化合物是埃坡霉素,一类抗肿瘤药物。本发明的埃坡霉素衍生物由式I代表:
其中:
P-Q是碳-碳双键或环氧化物;
G是
R选自氢、烷基和取代烷基;
R1选自
和
R2是
G1选自氢、卤素、CN、烷基和取代烷基;
G2选自氢、烷基和取代烷基;
G3选自O、S、NZ1基团;
G4选自氢、烷基和取代烷基、OZ2、NZ2Z3、Z2C=O、Z4SO2基团,和任选被取代的葡糖基;
G5选自卤素、N3、NCS、SH、CN、NC、N(Z1)3 +和杂芳基;
G6选自氢、烷基和取代烷基、CF3、OZ5、SZ5,或NZ5Z6基团;
G7是CZ7或N;
G8选自氢、卤素、烷基、取代烷基、OZ10、SZ10、NZ10Z11基团;
G9选自O、S、-NH-NH-和-N=N-基团;
G10是N或CZ12基团;
G11选自H2N、取代H2N、烷基、取代烷基、芳基和取代芳基;
每个Z1、Z6、Z9和Z11分别独立选自氢、烷基、取代烷基、酰基和取代酰基;
Z2选自氢、烷基、取代烷基、芳基、取代芳基以及杂环;
每个Z3、Z5、Z8以及Z10分别独立选自氢、烷基、取代烷基、酰基、取代酰基、芳基以及取代芳基;
Z4选自烷基、取代烷基、芳基、取代芳基以及杂环;
Z7选自氢、卤素、烷基、取代烷基、芳基、取代芳基、OZ8、SZ8和NZ8Z9基团;以及
Z12选自氢、卤素、烷基、取代烷基、芳基以及取代芳基;
当R1是如下结构时,
G1、G2、G3和G4不能同时具有下列意义:
G1和G2是氢,G3是氧,G4是氢或Z2C=O基团,其中Z2是烷基及其药物可接受的盐和任何水合物、溶剂化物或其几何、光学和立体异构体。
根据本发明,优选的化合物是式Ia代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G1是氢、烷基、取代烷基或卤素原子;
G2是氢、烷基或取代烷基;
G3是氧原子、S原子或NZ1基团;
Z1是氢、烷基、取代烷基、酰基或取代酰基;
G4是氢、烷基、取代烷基、OZ2基团、NZ2Z3、Z2C=O、Z4SO2基团,和任选被取代的葡糖基;
Z2是氢、烷基、取代烷基、芳基、取代芳基或杂环基;
Z3是氢、烷基、取代烷基、酰基或取代酰基;以及
Z4是烷基、取代烷基、芳基、取代芳基或杂环基;
前提条件为:G1、G2、G3和G4不能同时具有下列意义:
G1和G2是氢,G3是氧,G4是氢或Z2C=O基团,其中Z2是烷基。
根据本发明,更优选的化合物组是式Ib代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G1是氢、烷基、取代烷基或卤素原子;
G2是氢、烷基或取代烷基;
G5是卤素原子、N3基、NCS基、SH基、CN基、NC基或杂环基。
根据本发明,另一更优选的化合物组是式IIa代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G6是氢、烷基、取代烷基或CF3、OZ5、SZ5或NZ5Z6基团;
Z5是氢、烷基、取代烷基、酰基或取代酰基;
Z6是氢、烷基或取代烷基;
G7是CZ7基或氮原子;
Z7是氢、卤素原子、烷基、取代烷基、芳基或取代芳基,或OZ8、SZ8或NZ8Z9基团;
Z8是氢、烷基、取代烷基、酰基或取代酰基;
Z9是氢、烷基或取代烷基;
G8是氢、卤素原子、烷基、取代烷基,或OZ10、SZ10、NZ10Z11基团;
Z10是氢、烷基、取代烷基、酰基、取代酰基、芳基或取代芳基;以及
Z11是氢、烷基、取代烷基、酰基或取代酰基。
在本发明范围内,另一组更优选的化合物组是式IIb代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G6是氢、烷基、取代烷基,或CF3、OZ5、SZ5或NZ5Z6基团;
Z5是氢、烷基、取代烷基、酰基或取代酰基;
Z6是氢、烷基或取代烷基;以及
G9是氧原子或硫原子,或-N=N-基。
根据本发明,另一优选的化合物组是式III代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G10是氮原子或CZ12基;以及
Z12是氢、卤素原子、烷基、取代烷基、芳基或取代芳基。
根据本发明,附加的另一优选的化合物组是式IV代表的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;以及
G11是H2N基、取代H2N基、烷基、取代烷基、芳基或取代芳基。
根据本发明,特别优选的化合物组如下:
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(叠氮基甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环-[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-(2-氨甲基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[(1,1-二甲基乙氧基)羰基]氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-[[[(1,1-二甲基乙氧基)羰基]氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,1 3-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(氨甲基)-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,13-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(戊酰氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(萘甲酸基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-[[(2-甲氧基乙氧基)乙酰氧基]甲基]-1-甲基-4-噻唑基]乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-(N-丙酰氨基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(3-乙酰基-2,3-二氢-2-亚甲基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮,N-氧化物;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(甲氧甲基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,10,12,16-五甲基-3-[1-甲基-2-[2-[(苯氧甲基)-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(乙硫基)甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(乙氧甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(2,3,4,6-四乙酰基-α-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2[2-[(2′,3′,4′,6′-四乙酰基-β-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(6′-乙酰基-α-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-[2-[2-[对甲苯磺酰氧基]甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(溴甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(5-溴-2-甲基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟基-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(氰甲基)-4-噻唑基]-1-甲基乙烯基]-7,11]-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(氰甲基)-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,13-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(1H-咪唑-1-基-甲基)-4-噻唑基]-1-甲基乙烯基]-8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-甲酰基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟基-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-甲酰基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙烯基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(甲氧亚氨基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(苯甲基)亚氨基]甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙酰基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-(2-环氧乙基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(2-碘乙烯基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙炔基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-[2-[(甲氨基)甲基]-4-噻唑基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[2-(二甲氨基)乙基]氨基]甲基]-4-噻唑基-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(二甲氨基)甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8, 8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[双(甲氧乙基)氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-[2-[(4-甲基-1-哌嗪基)甲基]-4-噻唑基]乙烯基]-4,17]-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-二羟基-8,8,10,12-四甲基-5,9-二氧代-4,17-二噁二环[14.1.0]十七烷-3-基)-1-丙烯基]-2-噻唑羧酸;以及
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-二羟基-8,8,10,12-四甲基-5,9-二氧代-4,17-二噁二环[14.1.0]十七烷-3-基)-1-丙烯基]-2-噻唑羧酸甲酯。
根据本发明,特别优选的化合物是下式:
此化合物是[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟基-8,8,10,12,16-五甲基-3-[1-甲基-2-(2-氨甲基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮。
上述式I代表的埃坡霉素衍生物是已知化合物。这些化合物和它们的制备方法公开在WO 00/50423。然而迄今一直未得知本发明的埃坡霉素衍生物具有治疗用其它已知化疗剂有抗药性的肿瘤的活性。
下面是用于描述上述的式I化合物的术语。术语“烷基”指任选被取代的具有1个至约20个碳原子,优选1至约7个碳原子的直链或支链饱和烃基。“低级烷基”指具有1个至约4个碳原子的任选被取代的烷基。
术语“取代烷基”指被取代的烷基,例如被1-4个取代基取代,如卤素、三氟甲基、三氟甲氧基、羟基、烷氧基、环烷氧基、杂环氧基、氧代、烷酰基、芳基、芳氧基、芳烷基、烷酰氧基、氨基、烷氨基、芳氨基、芳烷氨基、环烷氨基、杂环氨基、二取代氨基,其中氨基上的二取代基选自烷基、芳基、芳烷基、烷酰氨基、芳酰氨基、芳烷酰氨基、取代烷酰氨基、取代芳氨基、取代芳烷酰氨基、硫醇基、烷基硫基、芳基硫基、芳烷硫基、环烷硫基、杂环硫基、烷基硫羰基、芳基硫羰基、芳烷基硫羰基、烷基磺酰基、芳基磺酰基、芳烷基磺酰基、磺酰胺(如SO2NH2)、取代磺酰胺基、硝基、氰基、羧基、氨基甲酰基(如CONH2)、取代氨基甲酰(如CONH烷基、CONH芳基、CONH芳烷基,或氮原子上二个取代基选自烷基、芳基或芳烷基的情况)、烷氧羰基、芳基、取代芳基、胍基和杂环基,如吲哚基、咪唑基、呋喃基、噻吩基、噻唑基、吡咯烷基、吡啶基、嘧啶基等。其中,如上所述,取代基本身可进一步被取代,这样的进一步取代基选自卤素、烷基、烷氧基、芳基以及芳烷基。在此所述的烷基和取代烷基也用于烷氧基的烷基部分。
术语“链烯基”指任选被取代的不饱和脂肪烃基,具有从1个至大约9个碳原子以及一个或多个双键。取代基可以包括一个或多个如上所述取代烷基的取代基团。
术语“卤素”或“卤”指氟、氨、溴以及碘。
术语“环状体系”指任选被取代的包含1-3环,并且至少在一个环上有至少一个碳碳双键的环状体系。示例的环状体系包括、但是不局限于芳基,或部分或完全不饱和的可任选被取代的杂环体系。
术语“芳基”指在环部分具有从大约6个到大约12个碳原子的单环或二环的芳烃基,例如:苯基、萘基、联苯和二苯基,每个芳烃基可以被取代。
术语“芳烷基”指通过烷基连接到更大的基团的芳基,比如苯甲基。
术语“取代芳基”指被取代的芳基,例如被1-4个取代基取代,如烷基、取代烷基、卤素、三氟甲基、三氟甲氧基、羟基、烷氧基、环烷氧基、杂环氧基、烷酰基、烷酰氧基、氨基、烷氨基、二烷氨基、芳烷氨基、环烷氨基、杂环氨基、烷酰氨基、硫醇基、烷基硫基、环烷硫基、杂环硫基、脲基、硝基、氰基、羧基、羧基烷基、氨基甲酰基、烷氧羰基、烷基硫羰基、芳基硫羰基、烷基磺酰基、磺酰胺基、芳氧基等。取代基可以更进一步被一个或多个基团取代,这些取代基选自卤素、羟基、烷基、烷氧基、芳基、取代烷基、取代芳基和芳烷基。
术语“环烷基”指任选被取代的饱和环烃环状体系,优选包含1个至大约3个环,每环大约3至7个碳原子,可以进一步与不饱和的C3-C7碳环稠合。示例的基团包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环癸基、环十二烷基和金刚烷基。示例的取代基包括一个或多个如上所述烷基,或一个或多个如上所述烷基取代基。
术语“杂环”(heterocycle、heterocyclic和heterocyclo)指任选被取代的不饱和、部分饱和、或完全饱和的,芳香族或非芳香族的环状基团,例如4-7员环单环、7-11员二环或10-15员三环,其中在至少一个含碳原子环上有至少一个杂原子。每个杂环基可含有1、2或3个杂原子,其选自氮原子、氧原子和硫原子,氮和硫杂原子也可任选被氧化,氮杂原子也可以任选被季铵化。杂环基可以连接在任何杂原子或碳原子上。
单环杂环基包括吡咯烷基、吡咯基、吲哚基、吡唑基、oxetanyl、吡唑啉基、咪唑基、咪唑啉基、咪唑烷基、噁唑基、噁唑烷基、异噁唑烷基、异噁唑基、噻唑基、噻二唑基、噻唑烷基、异噻唑基、异噻唑烷基、呋喃基、四氢呋喃基、噻吩基、噁二唑基、哌啶基、哌嗪基、2-氧哌嗪基、2-氧哌啶基、2-氧代吡咯烷基、2-氧氮杂基、氮杂基、4-哌啶酮基、吡啶基、氮-氧吡啶基、吡嗪基、嘧啶基、哒嗪基、四氢吡喃基、四氢硫代吡喃基、四氢硫代吡喃砜、吗啉基、硫代吗啉基、硫代吗啉基亚砜、硫代吗啉基砜、1,3-二氧戊环和四氢-1,1-二氧噻吩基、二噁烷基、异噻唑烷基、硫杂环丁烷基、硫杂丙环基、三嗪基以及三唑基等等。
示例的二环杂环基包括苯并噻唑基、苯并噁唑基、苯并噻吩基、奎宁啶基、喹啉基、喹啉基-N-氧化物、四氢异喹啉基、异喹啉基、苯并咪唑基、苯并吡喃基、中氮茚基、苯并呋喃基、色酮基、香豆素基、噌啉基、喹喔啉、吲唑基、吡咯并吡啶基、呋喃并吡啶基(如呋喃并2,3-c]吡啶基、呋喃并[3,1-b]吡啶基]或呋喃并[2,3-b]吡啶基)、二氢异吲哚基、二氢喹唑啉基(如3,4-二氢-4-氧-喹唑啉基)、苯基异噻唑基、苯基异噁唑基、苯并二嗪基、苯并呋咱基、苯并硫代吡喃基、苯并三唑基、苯基吡唑基、二氢苯并呋喃基、二氢苯并噻吩基、二氢苯并硫代吡喃基、二氢苯并苯吡喃基、二氢苯并吡喃基砜、二氢苯并苯吡喃基、二氢吲哚基、异苯并二氢吡喃基、异二氢吲哚基、1,8-二氮杂萘基、2,3-二氮杂萘基、胡椒基、嘌呤基、吡啶并吡啶基、喹唑啉基、四氢喹啉基、噻吩并呋喃基、噻吩并吡啶基、噻吩并噻吩基等等。
术语“环状体系”、“杂环”(heterocycle、heterocyclic、heterocyclo)中示例的取代基包括一个或多个如上所述取代烷基或取代芳基的取代基团,和比较小的杂环,如环氧化物、氮丙啶等等。
术语“烷酰基”指-C(O)-烷基。
术语“取代烷酰基”指-C(O)-取代烷基。
术语“杂原子”包括氧、硫和氮。
式I化合物与各种有机和无机酸形成盐。这种盐包括用氯化氢、溴化氢、甲磺酸、羟基乙磺酸、硫酸、乙酸、三氟乙酸、马来酸、苯磺酸、甲苯磺酸和本领域技术人员所知的各种其它制药技术所用酸制成的盐。通过将式I化合物与当量数的酸反应形成盐,反应在一种可沉淀出盐的介质中进行,或在一种水介质中形成盐,然后蒸发。另外,两性离子(“内盐”)也可包括在此处所用的术语“盐”中,而且在此包括式I化合物的溶剂化物和水合物。
式I化合物可以以多种光学、几何和立体异构体形式存在。当所示化合物在此描述出一种光性方位时,也表示包括本发明全部异构体及其混合物。
认识到上述式I化合物是微管稳定剂。因此它们用于治疗各种癌及其他增生性疾病,这些疾病包括但不限于如下所述疾病:
癌,包括膀胱、乳房、结肠、肾、肝、肺、卵巢、胰腺、胃、宫颈、甲状腺和皮肤癌,包括鳞状细胞癌在内;
淋巴系统的造血瘤,包括白血病、急性淋巴细胞性白血病、急性淋巴母细胞性白血病、B细胞淋巴瘤、T细胞淋巴瘤、何杰金淋巴瘤、非何杰金淋巴瘤、毛细胞淋巴瘤,和Burketts淋巴瘤;
骨髓系统的造血瘤,包括急性和慢性粒细胞性白血病以及早幼粒细胞性白血病;
间质起源的肿瘤,包括纤维肉瘤和横纹肌肉瘤;
其它肿瘤、包括黑素瘤、精原细胞瘤、畸胎癌、成神经细胞瘤和神经胶质瘤;
中枢和外周神经系统肿瘤,包括星形细胞瘤、成神经细胞瘤、神经胶质瘤,和许旺氏细胞瘤;
间质起源的肿瘤,包括纤维肉瘤、横纹肌肉瘤和骨肉瘤;
其它肿瘤,包括黑素瘤、着色性干皮病、角化棘皮瘤、精原细胞瘤、甲状腺滤泡癌和畸胎癌。
在此举出上述适应症,因为不能确定是上述哪一种类型的肿瘤以及其它类型的肿瘤可能证明对肿瘤治疗产生抗药性。“肿瘤治疗”指用在细胞中起到细胞毒素性作用的化疗剂治疗肿瘤。化疗剂的一个例子是紫杉烷族化合物肿瘤药物。例如,已知用紫杉烷化合物治疗肿瘤开始有效的大量病人在经过一个阶段治疗后产生抗药性,而且并不是所有癌症用紫杉烷治疗有作用。实际上,所有肿瘤药物都有此情况。此外,某些疾病,比如已知结肠直肠癌或黑素瘤对紫杉烷治疗有先天的抗药性。
本发明埃坡霉素化合物是非常有效的细胞毒性剂,在毫微克的低浓度能够杀死癌细胞,在诱导微管蛋白聚合方面的作用大约是紫杉醇的两倍。更重要的是,在对紫杉醇天然不敏感或产生抗药性的人类癌症方面,本发明化合物看来在体外和体内均具有保持其抗肿瘤活性的能力。
本发明埃坡霉素化合物对下列肿瘤但又不限于下列肿瘤显示出重要的抗癌活性,这些肿瘤包括:
[1]紫杉醇抗药性-HCT 116/VM46结肠直肠肿瘤(多种药物抗药性,MDR)、Pat-21乳腺癌和Pat-7卵巢癌(临床分离物,抗药性机理未完全明了)、A2780 Tax卵巢癌(微管蛋白突变);
[2]对紫杉醇不敏感-Pat-26人类胰腺癌(临床分离物)和M5076鼠纤维肉瘤;和
[3]对紫杉醇敏感-A2780卵巢癌、LS174T和HCT人类结肠癌。
此外,式I化合物在免疫受损小鼠或大鼠实验中证明对临床前人类肿瘤异种移植口服有效。口服有效是本发明埃坡霉素衍生物的重要的优点。
因此本发明提供了一种对哺乳动物,尤其是人类的肿瘤治疗方法,所述肿瘤是证明对紫杉烷族肿瘤药物治疗产生抗药性的肿瘤,该方法包括给予本发明的一种有效量的式I结构的埃坡霉素化合物用于治疗。可用如下所述的其它治疗剂以其通常剂量,与本发明埃坡霉素化合物一起使用。这些药物可以先用、同时用或在本发明埃坡霉素化合物服用后使用。
一个本领域普通技术人员可以确定式I代表的埃坡霉素化合物的有效量,示范性的人用剂量是大约0.05到大约200mg/kg/day。此剂量是一般的单剂量,也可以均分剂量给药,因为本发明化合物经口服有效。化合物可以多次的方式给药,如每两天给药五次,或间歇地给药,如每四天给药三次或每八天给药三次。应该理解,对于一个对象,服用的特定剂量和频率可以根据多种因素而改变,包括用药者的年龄、体重、一般健康状况、性别、日常饮食等、非口服时的服用方式、症状的严重程度等。
式I化合物以含对癌症治疗有效量的药物和药物可接受的载体的药物组合物方式服用。这样的组合物中可以包含如下所述的其它治疗剂,并且可以配制,例如:根据众所周知的药物配方技术和/或可接受的制药实践,使用常规的固体或液体载体或稀释剂,以及适于服用要求的药物添加剂类型(例如赋形剂、粘合剂、防腐剂、稳定剂、矫味剂等等)。
式I化合物可以任何合适的方法服用,例如口服,如以片剂、胶囊剂、颗粒剂或粉末的形式;舌下给药;口含方式给药;不经胃肠道给药,比如皮下、静脉内、肌内给药或胸骨内注射,或输液方法(如以含水或非水溶液或悬浮的无菌注射溶液);经鼻给药,如吸入喷雾;局部给药,如以乳膏剂或软膏形式;或直肠给药,如用栓剂形式;以含无毒的、药物可接受的载体或稀释剂的剂量单位配方方式。本发明化合物可以采用适于速释或缓释的形式。通过利用适当的含本发明化合物的药物组合物可以达到速释或缓释,特别是通过利用某些装置,如皮下植入物或渗透泵可达到缓释效果。本发明化合物还可以微脂粒形式服用。
本发明埃坡霉素衍生物适当的剂型包括但不限于口服有效的每一单位剂量含大约5-500mg式I化合物的组合物,如片剂、胶囊剂、溶液或悬浮液,或局部方式(式I化合物重量的约0.01%~约5%,每日治疗1-5次)。它们可以以常规的方式与生理上可接受的载体、赋形剂、粘合剂、防腐剂、稳定剂、矫味剂等混合,或与外用药的载体混合。式I化合物还可以是配制为经胃肠道外用药的组合物,如无菌溶液或悬浮液。可用大约0.1mg-大约500mg的式I化合物与一种生理可接受的载体、赋形剂、粘合剂、防腐剂、稳定剂等,正如所要求的以可接受的制药实践制备成单位剂量形式。在这些组合物或制剂中,活性物质的量优选在指定剂量的范围内。
示例的口服组合物包括悬浮液,例如可以含起疏松作用的微晶纤维素;海藻酸或海藻酸钠作为助悬剂;甲基纤维素作为增粘剂;以及本领域技术已知的甜味剂或调味剂;速释片可以包含例如:微晶纤维素、磷酸二钙、淀粉、硬脂酸镁和/或乳糖和/或其它赋形剂、粘合剂、填料、崩解剂、稀释剂以及本领域技术已知的润滑剂。可以应用的示例的形式是模制片、压制片或冻干的片剂。示例的组合物包括用速溶的稀释剂,如甘露醇、乳糖、蔗糖和/或环糊精配制的本发明化合物。还包括高分子量赋形剂,如纤维素(Avicel)或聚乙二醇(PEG)。这种配制剂可能同时包括产生粘合性的赋形剂,如羟丙基纤维素(HPC)、羟丙基甲基纤维素(HPMC)、羧基甲基纤维素钠(SCMC)、马来酐共聚物(如Cantrez)和控释剂,如聚丙烯酸共聚物(如卡巴浦尔934)。也可加入润滑剂、助流剂、矫味剂、着色剂和稳定剂,便于成型和使用。
示范性的鼻喷雾剂或吸入剂包括生理盐水溶液,可以含有例如苯甲醇或其它适当的防腐剂、吸收促进剂,以提高生物利用度,和/或本领域已知的其它增溶或分散剂。
示范性的胃肠外用药组合物包括可注射的溶液或悬浮液,含有例如,适当的无毒胃肠外用药可接受的稀释剂或溶剂,如Cremophor(聚氧乙烯化蓖麻油表面活性剂)、甘露醇、1,3-丁二醇、水、Ringer溶液、Ringer乳酸盐溶液、等渗氯化钠溶液,或其它适当的分散剂或湿润剂及助悬剂,包括合成的甘油一酯或二酯,以及包括油酸在内的脂肪酸。示范性的直肠用组合物包括栓剂,可含有例如适当的非刺激性赋形剂,比如可可脂、合成甘油酯或聚乙二醇,这些赋形剂在常温下为固体,但在直肠腔内液化和/或溶解,释放出药物。
本发明的化合物可以单独服用,或与其它化疗剂或抗癌剂和细胞毒性剂和/或治疗对癌症或者其它增生性疾病有用的治疗方法结合使用。尤其有用的是抗癌药和细胞毒性药物联合使用,其中所选的第二种药以不同的方式或在不同的细胞周期如S期发生作用,而本发明的式I化合物是在G2-M期发挥作用。抗癌剂和细胞毒性剂包括但是不局限于:烷基化剂,比如氮芥类、烷基磺酸酯、亚硝基脲、吖丙啶和三氮烯;抗代谢物,如叶酸拮抗物、嘌呤类似物和嘧啶类似物;抗生素,如蒽环类抗生素、争光霉素、丝裂霉素、更生霉素和普卡霉素;酶,如左旋天冬酰胺酶;法呢基蛋白质转移酶抑制剂;激素类药物,如糖皮质激素、雌激素类/抗雌激素类、雄激素类/抗雄激素类、孕酮和黄体生成素释放激素拮抗剂、奥曲肽醋酸盐;微管破裂剂,如海鞘素类或它们的类似物以及衍生物;埃坡霉素A-F或它们的类似物或衍生物;植物衍生物,如长春花生物碱、表鬼臼脂素,以及拓扑异构酶抑制剂;异戊二烯基-蛋白质转移酶抑制剂;以及其他药物,如羟基脲、甲基苄肼、米托坦、六甲基蜜胺、铂配位络合物,如顺铂以及卡铂;及其他药物用作抗癌和细胞毒性药物,如生物应答改性剂、生长因子;免疫调节剂和单克隆抗体。本发明化合物还可用于与放射疗法结合。
式I化合物还可与其它治疗药物同时配制或服用,这些药物的选择是根据与上述疾病症状有关的治疗。例如本发明的化合物可与防止恶心、超敏性和胃刺激的药物一同配制,如止吐药、H1和H2抗组胺剂。
当与本发明的化合物联合使用时,上述治疗剂的用量可以参考Physicians’Desk Reference(PDR)中指出的用量,或由本领域普通技术人员确定用量。
举出下列实例,为更进一步说明本发明,而不是做出任何限制。
实施例
[1S-[1R*,3R*(E),7R*,10S*,I1R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-(2-氨甲基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮(BMS-310705)。
本发明化合物给啮齿类动物服用,或以1∶9乙醇/水,或者以1∶1∶8Cremophor/乙醇/水的浓度。胃肠外用药的最终稀释液是在使用一个小时之前用水制成的。最终口服稀释液用0.25M磷酸钠缓冲液制成(pH8.0)。将紫杉醇溶于乙醇和Cremophor各半(50/50)的混合溶剂中,并保持在4℃。最终稀释液制备后立即注射,以防止不合需要的沉淀出现。
肿瘤细胞系:将HCT 116人类癌细胞和HCT116/V/M46细胞保存在McCoy培养基中和10%热灭活的胎牛血清中。A2780人类卵巢癌细胞和A2780Tax细胞保持在IMBM和10%热灭活的胎牛血清中。此紫杉醇抗药性细胞系不超表达P-糖蛋白,但在β微管蛋白2的M40同种型有点突变。由此抗药性细胞分离出的纯化微管蛋白是难于用紫杉醇聚合的,所以被认为是因为对这种药物具有抗药性,并且同时对微管解聚剂如长春花碱敏感。所有其它细胞系都保存在加有10%热灭活胎牛血清的RPM11640培养基中。
细胞毒性试验:体内细胞毒性用肿瘤细胞做试验,以四唑氮法为基础,于492nm进行比色测定。在加入药物24小时之前,接种细胞。加入试剂后与系列稀释受试化合物一起温育72小时。再温育3小时后进行测定。结果以半数细胞中毒浓度(IC50值)表示。
克隆源性细胞群落-形成试验:用菌落形成试验体外评估受试化合物和紫杉醇杀死克隆源性肿瘤细胞(能不确定地分裂形成群落细胞)所需的效力。测定杀死90%的克隆源性癌细胞需要的浓度(IC90)。
微管蛋白聚合试验:用公开的方法评估受试化合物和紫杉醇聚合从小牛脑分离的微管蛋白的效力。有效浓度(EC0.01)被定义为能诱导光密度(OD)起始斜率0.01OD/分钟的插入浓度,用下式计算:EC0.01=浓度/斜率。EC0.01值表示为由3种不同浓度获得的带有标准差的均值。
体内抗瘤试验:使用下列人类肿瘤:卵巢A2780、卵巢A2780Tax和Pat-7(从对紫杉醇产生抗药性的患者的卵巢肿瘤组织活检中得到);和Pat-26胰腺癌(从肝转移组织活检中得到)。将人类肿瘤异种移植物保持在Balb/c nu/nu裸鼠体内。将从供体小鼠获得的肿瘤片段皮下植入适当的小鼠品系进行肿瘤转染。所有用于效果测试的肿瘤植入物都是在皮下的(sc)。在实验开始时,集中处理需要检测有意义反应(6-8)的所需若干动物,用13号规格的套管注射器将肿瘤片段(约50mg)植入皮下。为早期肿瘤的治疗,在将动物分为多种治疗组和对照组之前集中处理。为治疗有晚期肿瘤的动物,使肿瘤长到预先确定的大小(排除肿瘤外面范围),并将动物均匀分成多种治疗组和对照组。每个动物的治疗是以个体体重为基础的。每日检查治疗组动物的治疗相关毒性/死亡率。每组动物在开始治疗之前称重(Wt1),然后于最后一次剂量治疗后再称重(Wt2)。体重之差(Wt2-Wt1)是治疗相关毒性的一个指标值。
用卡钳每周两次测量肿瘤,直到达到预先确定的0.5g或1.0g的“目标”大小,以此确定肿瘤反应。肿瘤重量(毫克)用下式估算:
肿瘤重量=(长度×宽度2)/2
最大耐受剂量(MTD)定义为超过此的剂量水平则发生过高的毒性(如受试动物死亡1个以上)。MTD往往相当于最适剂量(OD)。在OD描述活性。肿瘤达到目标大小之前期满的治疗组小鼠被认为具有药物毒性。没有一个对照组小鼠期满时肿瘤小于目标大小。超过一个因药物毒性死亡的试验组被认为有过量毒性的治疗,它们的数据不包括化合物抗癌效力的估价之内。
肿瘤反应终点用肿瘤生长延迟(T-C值)的术语表示,T-C值定义为治疗组的肿瘤(T)与对照组的肿瘤(C)相比达到预定目标大小需要的时差(天数)。在研究终止的时候无可检出的肿瘤,则将肿瘤定义为“治愈”;研究终止和药物治疗结束之间的间隔始终超过肿瘤体积倍增时间的10倍。所有治疗组和对照组的大小一般由8只小鼠组成。用Gehan总结出的Wilcoxon检验法对反应数据进行统计学分析。
体外抗癌细胞细胞毒性:如图1所示,结果证明受试化合物具有广谱体外抗肿瘤细胞系活性。在8个受试细胞系中,7个IC50值范围在0.9nM-3.5nM。高多抗药性(MDR)结肠肿瘤系HCT/VM46的IC50值为11.9nM。应注意受试药物基本上克服了这些细胞的MDR。这可以从紫杉醇抑制细胞生长50%所需的浓度比(R/S或抗药性比)在抗药性细胞系对敏感HCT 116细胞系是155倍,而受试化合物仅12.8倍看出。
细胞毒性-微管蛋白聚合机理:埃坡霉素的细胞毒性活性如同紫杉烷的一样,已经与导致在G2/M过渡时有丝分裂停滞的微管稳定有关。在这点上受试化合物的作用大约是紫杉醇的2.5倍以上。4个埃坡霉素化合物的微管蛋白聚合作用见如下表1。
表1四种与紫杉醇相比较埃坡霉素的肿瘤聚合能力
类似物 | 聚合能力,EC0.01(μM) | 类似物/紫杉醇聚合能力比 |
BMS-310705 | 7.4 | 1.7 |
BMS-247550 | 3.5 | 0.4 |
BMS-212188(埃坡霉素A) | 2.0 | 0.4 |
BMS-205535(埃坡霉素B) | 1.8 | 0.3 |
表1中类似物的结构见图5。
胃肠外投药的抗肿瘤活性:用五种已知对紫杉醇表现抗药性特性的人类肿瘤异种移植物评价受试化合物。肿瘤模型(见表2)如下:临床得出的紫杉醇抗药性Pat-7卵巢癌;A2780Tax卵巢癌异种移植物(突变的微管蛋白);HCT116/VM46人类结肠癌异种移植物-多药抗药性(MDR);临床得出的紫杉醇抗药性Pat-21乳癌模型;和Pat-26人类胰腺癌模型。受试的本发明化合物保持其抗肿瘤活性并且比紫杉醇活性更强。这些结果见图2和3及表3。
表2肿瘤模型特征
肿瘤 | 组织学 | 紫杉醇敏感性 | 抗药性机理 | |
人类 | Pat-7 | 卵巢 | 抗药性1 | MDR,MRP2 |
A2780Tax | 卵巢 | 抗药性 | 微管蛋白突变 | |
HCT 116/VM46 | 结肠 | 抗药性 | MDR | |
Pat-21 | 乳房 | 抗药性1 | 未知 | |
Pat-26 | 胰腺 | 难于治疗 | 未知 |
1对TAXOL具有临床抗药性
2MRP=多药抗药性相关蛋白
表3BMS-310705和紫杉醇对紫杉醇抗药性肿瘤临床的抗肿瘤活性
肿瘤 | 实验号 | BMS-310705 | BMS-247550LCK2 | 紫杉醇3LCK2 | |||
给药途径方案 | OD1(mg/kg) | LCK2 | |||||
人类肿瘤在裸鼠 | Pat-7 | 14 | 静脉注射,q4dx3 | 8 | 2.4 | 1.8 | 0.8 |
A2 780 Tax | 13 | 静脉注射,q4dx3 | 10 | 3.6 | 3.5 | 0.8 | |
HCTVM46 | 40 | 静脉注射,q4dx3 | 7.5 | 1.5 | 1.3 | 0.55 | |
Pat-21 | 717 | 静脉注射,q4dx3;37,66 | 9 | >4.1 | 3.9 | 0.3 | |
Pat-26 | 968 | 静脉注射,q4dx3 | 10 | 1.2 | (1.2) | 0.4 |
1OD最佳剂量或最大耐受剂量(MTD)。
2LCK在最大耐受剂量(MTD)时总对数细胞杀灭率,如无活性时为最高剂量。
3在分别研究中紫杉醇所得的结果。
进行配方试验,以观察所用载体的效果。因为受试化合物是稳定的并且高度水溶性的,将单纯溶液的效果与相同浓度的受试药物在如上所述的Cremophor/乙醇/水的载体中进行了对比。未发现差异。
经口服药的抗肿瘤活性:由于受试化合物在中性pH比在低pH中更稳定,用pH缓冲载体(0.25m磷酸钾,pH 8.0)评价其口服(PO)效果。如图4所示,每4天3次服用,口服受试化合物对抗Pat-7人类卵巢癌肿模型是高活性的。如下表4所示,在其MTD下,口服受试化合物得到2.4LCK。不能用紫杉醇进行比较,因为紫杉醇经口服途径是无活性的。
表4口服BMS-310705和静脉注射BMS-247550的抗肿瘤活性
肿瘤 | 实验号 | BMS-310705(PO) | BMS-247550 LCK2 | ||
给药途径方案 | OD1(mg/kg) | LCK2(治愈/总数) | |||
Pat-7 | 18 | PO,q4dx3 | 90 | 2.4 | 1.9 |
1OD最佳剂量或最大耐受剂量(MTD)。
2LCK总对数细胞杀灭率。
从上述体外实验数据看出,受试化合物在对紫杉醇产生抗药性的癌细胞中保持其抗肿瘤活性,无论是否通过MDR P-糖蛋白超表达或微管蛋白突变。在此研究中,体内证据表明,在对五种紫杉醇抗药性肿瘤评价中,受试化合物已清楚地证明具有抗癌活性。
受试化合物优于原型紫杉烷的另一优点是口服有效,口服时具有相当于静脉注射药物产生的抗癌活性。
Claims (18)
1.一种治疗哺乳动物肿瘤的方法,所述肿瘤已被证明对肿瘤治疗产生抗药性,包括投予所述哺乳动物有效剂量的包括药物可接受的载体和一种式I的埃坡霉素化合物的组合物:
其中:
P-Q是碳-碳双键或环氧化物;
G是
R是选自氢、烷基和取代烷基的基团;
R1选自
R2是
G1选自氢、卤素、CN、烷基和取代烷基;
G2选自氢、烷基和取代烷基;
G3选自O、S、NZ1;
G4选自氢、烷基和取代烷基、OZ2,NZ2Z3、Z2C=O、Z4SO2,和任选被取代的葡糖基;
G5选自卤素、N3、NCS、SH、CN、NC、N(Z1)3 +和杂芳基;
G6选自氢、烷基、取代烷基、CF3、OZ5、SZ5和NZ5Z6;
G7是CZ7或N;
G8选自氢、卤素、烷基、取代烷基、OZ10、SZ10、NZ10Z11;
G9选自O、S、-NH-NH-和-N=N-;
G10是N或CZ12;
G11选自H2N、取代H2N、烷基、取代烷基、芳基和取代芳基;
每个Z1、Z6、Z9和Z11分别独立选自氢、烷基、取代烷基、酰基和取代酰基;
Z2选自氢、烷基、取代烷基、芳基、取代芳基以及杂环;
每个Z3、Z5、Z8以及Z10分别独立选自氢、烷基、取代烷基、酰基、取代酰基、芳基以及取代芳基;
Z4选自烷基、取代烷基、芳基、取代芳基以及杂环;
Z7选自氢、卤素、烷基、取代烷基、芳基、取代芳基、OZ8、SZ8和NZ8Z9;以及
Z12选自氢、卤素、烷基、取代烷基、芳基以及取代芳基;
前提条件是如果R1是如下结构,
G1、G2、G3和G4不能同时具有下列含义:
G1和G2是氢,G3是氧,G4是氢或Z2C=O,其中Z2是烷基及其药物可接受的盐和任何水合物、溶剂化物或其几何、光学和立体异构体。
2.权利要求1的方法,其中所述化合物是式Ia:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G1是氢、烷基、取代烷基或卤素原子;
G2是氢、烷基或取代烷基;
G3是氧原子、S原子或NZ1基团;
Z1是氢、烷基、取代烷基、酰基或取代酰基;
G4是氢、烷基、取代烷基、OZ2基团、NZ2Z3基团、Z2C=O基团、Z4SO2基团或任选被取代的葡糖基;
Z2是氢、烷基、取代烷基、芳基、取代芳基或杂环基;
Z3是氢、烷基、取代烷基、酰基或取代酰基;以及
Z4是烷基、取代烷基、芳基、取代芳基或杂环基;
前提条件为:G1、G2、G3和G4不能同时具有下列意义:
G1和G2是氢,G3是氧,G4是氢或Z2C=O,其中Z2是烷基。
4.权利要求1的方法,其中所述化合物是式IIa的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G6是氢、烷基、取代烷基或CF3、OZ5、SZ5或NZ5Z6基团;
Z5是氢、烷基、取代烷基、酰基或取代酰基;
Z6是氢、烷基或取代烷基;
G7是CZ7基或氮原子;
Z7是氢、卤素原子、烷基、取代烷基、芳基或取代芳基、或OZ8、SZ8或NZ8Z9基团;
Z8是氢、烷基、取代烷基、酰基或取代酰基;
Z9是氢、烷基或取代烷基;
G8是氢、卤素、烷基、取代烷基、OZ10、SZ10或NZ10Z11基团;
Z10是氢、烷基、取代烷基、酰基、取代酰基、芳基或取代芳基;
并且
Z11是氢、烷基、取代烷基、酰基或取代酰基。
6.权利要求1的方法,其中所述化合物是式III的化合物:
其中:
P-Q是碳-碳双键或环氧化物;
R是氢或甲基;
G10是氮原子或CZ12基;以及
Z12是氢、卤素原子、烷基、取代烷基、芳基或取代芳基。
8.权利要求1的方法,其中所述化合物选自:
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(叠氮甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环-[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-(2-氨甲基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[(1,1-二甲基乙氧基)羰基]氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-[[[(1,1-二甲基乙氧基)羰基]氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,13-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(氨甲基)-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,13-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(戊酰氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(萘甲酸基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-[[2-甲氧基乙氧基]乙酰氧基]甲基]-1-甲基-4-噻唑基]乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.01十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[N-丙酰氨基]甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(3-乙酰基-2,3-二氢-2-亚甲基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮,N-氧化物;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(甲氧甲基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,10,12,16-五甲基-3-[1-甲基-2-[2-[(苯氧甲基)-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(乙硫基)甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(乙氧甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(2,3,4,6-四乙酰基-α-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2[2-[(2′,3′,4′,6′-四乙酰基-β-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[(6′-乙酰基-α-葡糖氧基)甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-[2-[2-[对甲苯磺酰氧基]甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(溴甲基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(5-溴-2-甲基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟基-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(氰甲基)-4-噻唑基]-1-甲基乙烯基]-7,11]-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(氰甲基)-4-噻唑基]-1-甲基乙烯基]-4,8-二羟基-5,5,7,9,13-五甲基-1-氧杂-13(Z)-环十六碳烯-2,6-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(1H-咪唑-1-基-甲基)-4-噻唑基]-1-甲基乙烯基]-8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-甲酰基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟基-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-甲酰基)-4-噻唑基]-1-甲基乙烯基]-7,11-二羟-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙烯基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(甲氧亚氨基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-[2-[[(苯甲基)亚氨基]甲基]-4-噻唑基]乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙酰基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12-四甲基-3-[1-甲基-2-(2-环氧乙基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-3-[2-[2-(2-碘乙烯基)-4-噻唑基]-1-甲基乙烯基]-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-乙炔基-4-噻唑基)-1-甲基乙烯基]-7,11-二羟-8,8,10,12-四甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-[2-[(甲氨基)甲基]-4-噻唑基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[2-(二甲氨基)乙基]氨基]甲基]-4-噻唑基-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(二甲氨基)甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[双(甲氧乙基)氨基]甲基]-4-噻唑基]-1-甲基乙烯基]-7,11-二羟基-8,8,10,12,16-五甲基-4,17-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟-8,8,10,12,16-五甲基-3-[1-甲基-2-[2-[(4-甲基-1-哌嗪基)甲基]-4-噻唑基]乙烯基]-4,17]-二噁二环[14.1.0]十七烷-5,9-二酮;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-二羟基-8,8,10,12-四甲基-5,9-二氧代-4,17-二噁二环[14.1.0]十七烷-3-基)-1-丙烯基]-2-噻唑羧酸;以及
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-二羟基-8,8,10,12-四甲基-5,9-二氧代-4,17-二噁二环[14.1.0]十七烷-3-基)-1-丙烯基]-2-噻唑羧酸甲酯。
9.权利要求8的方法,其中所述化合物是:
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-二羟基-8,8,10,12,16-五甲基-3-[1-甲基-2-(2-氨甲基-4-噻唑基)乙烯基]-4,17-二噁二环[14.1.0]十七烷-5,9-二酮。
10.权利要求1的方法,其中所述埃坡霉素化合物的结构是:
11.权利要求1的方法,其中所述哺乳动物是人。
12.权利要求1的方法,其中含有所述埃坡霉素化合物的组合物是胃肠外用药。
13.权利要求12的方法,其中所述埃坡霉素化合物的结构是:
14.权利要求1的方法,其中含有所述埃坡霉素化合物的组合物是口服用药。
15.权利要求14的方法,其中所述埃坡霉素化合物的结构是:
16.权利要求1的方法,其中所述肿瘤对抗肿瘤治疗开始不反应。
17.权利要求1的方法,其中所述肿瘤对抗肿瘤治疗开始有反应,但在治疗过程中产生抗药性。
18.权利要求1的方法,其中所述化合物与用于治疗癌症或其它增生性疾病的化疗剂同时给药或先后给药。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26985801P | 2001-02-20 | 2001-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1610549A true CN1610549A (zh) | 2005-04-27 |
Family
ID=23028941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA028052447A Pending CN1610549A (zh) | 2001-02-20 | 2002-02-06 | 用于治疗难治肿瘤的埃坡霉素衍生物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US6727276B2 (zh) |
EP (1) | EP1368030A1 (zh) |
JP (1) | JP2004522771A (zh) |
KR (1) | KR20040028720A (zh) |
CN (1) | CN1610549A (zh) |
BG (1) | BG108072A (zh) |
BR (1) | BR0207316A (zh) |
CA (1) | CA2438598A1 (zh) |
EE (1) | EE200300397A (zh) |
HU (1) | HUP0400041A2 (zh) |
IL (1) | IL157128A0 (zh) |
IS (1) | IS6917A (zh) |
MX (1) | MXPA03007423A (zh) |
NO (1) | NO20033682D0 (zh) |
PL (1) | PL363363A1 (zh) |
RU (1) | RU2003128312A (zh) |
WO (1) | WO2002066033A1 (zh) |
ZA (1) | ZA200306237B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110105368A (zh) * | 2019-05-09 | 2019-08-09 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
BRPI0207961B8 (pt) * | 2001-03-14 | 2021-05-25 | Bristol Myers Squibb Co | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7384964B2 (en) * | 2002-08-23 | 2008-06-10 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP2186811A1 (en) | 2002-08-23 | 2010-05-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7091193B2 (en) | 2002-10-09 | 2006-08-15 | Kosan Biosciences Incorporated | Therapeutic formulations |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
AR052142A1 (es) * | 2004-11-18 | 2007-03-07 | Bristol Myers Squibb Co | Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma |
US20060134214A1 (en) * | 2004-11-18 | 2006-06-22 | Ismat Ullah | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
WO2007130501A2 (en) | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
NZ572836A (en) | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
EP1440973A3 (de) | 1995-11-17 | 2004-10-20 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, Herstellung und Mittel |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
CN1544436A (zh) | 1997-02-25 | 2004-11-10 | ���\���о�����˾��GBF�� | 3,7-保护的环氧噻嗪酮-n-氧化物及其制备方法 |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
JP4065573B2 (ja) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ATE224882T1 (de) | 1997-07-16 | 2002-10-15 | Schering Ag | Thiazolderivate, verfahren zur herstellung und verwendung |
CA2299608A1 (en) | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
SK287487B6 (sk) | 1998-02-05 | 2010-11-08 | Novartis Ag | Lyofilizovaná kompozícia a rekonštituovaná lyofilizovaná kompozícia |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
IL143069A0 (en) | 1998-11-20 | 2002-04-21 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
CA2352505C (en) | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
PL349863A1 (en) | 1999-02-18 | 2002-09-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
BR0008379A (pt) * | 1999-02-22 | 2002-09-24 | Biotechnolog Forschung Gmbh | Epotilonas modificadas em c-21 |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
-
2002
- 2002-02-06 RU RU2003128312/14A patent/RU2003128312A/ru not_active Application Discontinuation
- 2002-02-06 PL PL02363363A patent/PL363363A1/xx not_active Application Discontinuation
- 2002-02-06 CA CA002438598A patent/CA2438598A1/en not_active Abandoned
- 2002-02-06 KR KR10-2003-7010872A patent/KR20040028720A/ko not_active Application Discontinuation
- 2002-02-06 HU HU0400041A patent/HUP0400041A2/hu unknown
- 2002-02-06 BR BR0207316-1A patent/BR0207316A/pt not_active Application Discontinuation
- 2002-02-06 MX MXPA03007423A patent/MXPA03007423A/es unknown
- 2002-02-06 WO PCT/US2002/004247 patent/WO2002066033A1/en not_active Application Discontinuation
- 2002-02-06 IL IL15712802A patent/IL157128A0/xx unknown
- 2002-02-06 EP EP02724940A patent/EP1368030A1/en not_active Withdrawn
- 2002-02-06 JP JP2002565591A patent/JP2004522771A/ja active Pending
- 2002-02-06 EE EEP200300397A patent/EE200300397A/xx unknown
- 2002-02-06 CN CNA028052447A patent/CN1610549A/zh active Pending
- 2002-02-08 US US10/071,988 patent/US6727276B2/en not_active Expired - Fee Related
-
2003
- 2003-08-07 BG BG108072A patent/BG108072A/xx unknown
- 2003-08-12 ZA ZA200306237A patent/ZA200306237B/en unknown
- 2003-08-18 IS IS6917A patent/IS6917A/is unknown
- 2003-08-19 NO NO20033682A patent/NO20033682D0/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110105368A (zh) * | 2019-05-09 | 2019-08-09 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
CN110105368B (zh) * | 2019-05-09 | 2022-01-07 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
HUP0400041A2 (hu) | 2004-04-28 |
ZA200306237B (en) | 2004-12-23 |
US6727276B2 (en) | 2004-04-27 |
US20020165257A1 (en) | 2002-11-07 |
WO2002066033A1 (en) | 2002-08-29 |
JP2004522771A (ja) | 2004-07-29 |
EP1368030A1 (en) | 2003-12-10 |
CA2438598A1 (en) | 2002-08-29 |
EE200300397A (et) | 2003-12-15 |
MXPA03007423A (es) | 2003-11-18 |
NO20033682L (no) | 2003-08-19 |
NO20033682D0 (no) | 2003-08-19 |
RU2003128312A (ru) | 2005-02-10 |
BR0207316A (pt) | 2004-02-10 |
IS6917A (is) | 2003-08-18 |
PL363363A1 (en) | 2004-11-15 |
IL157128A0 (en) | 2004-02-08 |
KR20040028720A (ko) | 2004-04-03 |
BG108072A (en) | 2005-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1610549A (zh) | 用于治疗难治肿瘤的埃坡霉素衍生物 | |
CN1774253A (zh) | 用环氧丙酯酮衍生物治疗顽固性肿瘤 | |
CN1196484C (zh) | 联合用作抗癌剂的药物组合物 | |
CN1496256A (zh) | 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合 | |
CN1419452A (zh) | 协同治疗癌症的方法和组合物 | |
CN1268336C (zh) | 用于口服给予埃坡霉素的药用组合物、剂型以及方法 | |
US20060235006A1 (en) | Combinations, methods and compositions for treating cancer | |
JP2004529904A5 (zh) | ||
EP1483251B1 (en) | C3-cyano epothilone derivatives | |
CN1893919A (zh) | 局部施用的杀体内寄生虫组合物 | |
CN1622814A (zh) | 抗肿瘤活性吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物的联合应用 | |
WO2003084536A1 (en) | Oral administration of epothilones | |
CN1649587A (zh) | 埃坡霉素在与增殖过程有关的脑病的治疗中的用途 | |
CN1849119A (zh) | 用于增生性疾病的治疗的src激酶抑制剂和化学治疗剂的组合 | |
WO2007140299A2 (en) | Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals | |
JP2007504259A (ja) | エポチロンでの癌処置 | |
CN1178663C (zh) | 1,4-苯并硫氮杂�衍生物作为抗癌药抗性克服用药物的用途 | |
EP1392296A1 (en) | Thiazolidinediones alone or in conbination with other therapeutic agents for inhibiting or reducing tumour growth | |
AU2004251444B2 (en) | Cancer treatment with epothilones | |
CN1752078A (zh) | 埃博霉素类似物、其制备方法、药物组合物及用途 | |
CN1882594A (zh) | 含有稠合吡咯并咔唑的成颗粒组合物 | |
AU2002255539A1 (en) | Epothilone derivatives for the treatment of refractory tumors | |
CN1173331A (zh) | 制备动物用驱寄生虫药组合物的方法 | |
CN1694691A (zh) | 用蒽环类和紫杉烷类治疗转移性乳癌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |